LeMaitre Vascular (NASDAQ:LMAT) Stock

LeMaitre Vascular

LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.

Apple September 9 'Glowtime' Event: Here's Everything Cupertino Is Expected To Launch

News

Price Target

Markets

Analyst Ratings

Trading Ideas

AAPL

AMZN

LMAT

NCLH

PATK

Apple To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Friday

Stock market analysts

Initiation

SNPS

This Synopsys Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Earnings

Earnings Beats

Mid Cap

Health Care

Small Cap

Management

General

ACHC

AVNS

ENSG

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) and Methodist Jennie Edmundson Hospital recently conducted a groundbreaking ceremony for a cutting-edge behavioral health hospital in Council Bluffs, IA.

Acadia Healthcare Expands Behavioral Health Services in Iowa

LeMaitre Vascular Inc

Wells Fargo analyst Nathan Treybeck initiates coverage on LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) with a Equal-Weight rating and announces Price Target of $95.

Wells Fargo Initiates Coverage On LeMaitre Vascular with Equal-Weight Rating, Announces Price Target of $95

LeMaitre Vascular Appointed As CFO, Effective March 10, 2025

<h3>Gainers</h3>
<ul>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares increased by 178.2% to $9.04 during Tuesday's pre-market session. The company's market cap stands at $10.1 million. </li>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares moved upwards by 137.73% to $1.26. The market value of their outstanding shares is at $235.4 million. </li>
<li>Camp4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) shares rose 39.15% to $8.85. The company's market cap stands at $178.4 million. </li>
<li>Akari Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKTX#NASDAQ">AKTX</a>) stock rose 27.53% to $1.26. The market value of their outstanding shares is at $33.3 million. </li>
<li>Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) shares moved upwards by 19.13% to $19.67. The market value of their outstanding shares is at $22.2 billion. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock rose 17.99% to $1.18. The market value of their outstanding shares is at $4.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vaccinex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCNX#NASDAQ">VCNX</a>) stock decreased by 47.7% to $1.91 during Tuesday's pre-market session. The market value of their outstanding shares is at $5.1 million. </li>
<li>Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) shares decreased by 38.27% to $1.42. The company's market cap stands at $47.4 million. </li>
<li>PepGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEPG#NASDAQ">PEPG</a>) shares decreased by 33.49% to $3.0. The market value of their outstanding shares is at $97.7 million. </li>
<li>Tenaya Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNYA#NASDAQ">TNYA</a>) stock declined by 31.25% to $1.98. The company's market cap stands at $156.8 million. </li>
<li>LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) stock declined by 23.79% to $70.19. The market value of their outstanding shares is at $1.5 billion. </li>
<li>Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) shares decreased by 12.49% to $5.12. The company's market cap stands at $185.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AKTX

BMEA

CAMP

PEPG

PLRZ

PRTG

RVPH

TEVA

TNXP

TNYA

VCNX

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Reported Earlier, LeMaitre Vascular Announces $150M 2.50% Convertible Senior Notes Due 2030, With 30% Premium Conversion Pricing

LeMaitre Vascular, Inc. ("LeMaitre") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) today announced its intention to offer, subject to market and other conditions, $150,000,000 aggregate principal amount of Convertible Senior Notes due 2030 (the "notes") in a private offering (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). LeMaitre also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $22,500,000 aggregate principal amount of notes.

Offerings

LeMaitre Vascular Announces Proposed $150M Aggregate Principal Amount Of Convertible Senior Notes Due 2030

A large exercise of company stock options by James John OConnor, Director at LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) was disclosed in a new SEC filing on November 27, as part of an insider exercise.
What Happened: In an insider options sale disclosed in a Form 4 filing on Wednesday with the <a href="https://www.sec.gov/Archives/edgar/data/0001158895/000143774924036352//Archives/edgar/data/1158895/000143774924036352/0001437749-24-036352-index.htm">U.S. Securities and Exchange Commission</a>, OConnor, Director at LeMaitre Vascular, exercised stock options for 7,500 shares of LMAT. The transaction value amounted to $527,400.
LeMaitre Vascular shares are trading up 0.36% at $105.8 at the time of this writing on Thursday morning. Since the current price is $105.8, this makes OConnor's 7,500 shares worth $527,400.
<h3>All You Need to Know About LeMaitre Vascular</h3>
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.
<h3>LeMaitre Vascular: Delving into Financials</h3>
Revenue Growth: LeMaitre Vascular displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 15.63%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 67.82%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): LeMaitre Vascular's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 0.5.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.06, LeMaitre Vascular adopts a prudent financial strategy, indicating a balanced approach to debt management.
Valuation Metrics: A Closer Look
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 57.93, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 11.21, LeMaitre Vascular's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio lower than industry averages at 36.81, LeMaitre Vascular could be considered undervalued.
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Navigating the Impact of Insider Transactions on Investments</h3>
In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Cracking Transaction Codes</h3>
Digging into the details of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their attention to those taking place in the open market, as outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001158895">Check Out The Full List Of LeMaitre Vascular's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Strategic Sale: James John OConnor Decides To Exercise Options Worth $527K At LeMaitre Vascular

A large exercise of company stock options by George LeMaitre, Chairman and CEO at LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) was disclosed in a new SEC filing on November 26, as part of an insider exercise.
What Happened: LeMaitre, Chairman and CEO at LeMaitre Vascular, made a strategic move by exercising stock options for 2,818 shares of LMAT as detailed in a Form 4 filing on Tuesday with the <a href="https://www.sec.gov/Archives/edgar/data/0001158895/000143774924036268//Archives/edgar/data/1158895/000143774924036268/0001437749-24-036268-index.htm">U.S. Securities and Exchange Commission</a>. The transaction value amounted to $187,101.
LeMaitre Vascular shares are trading down 0.0% at $105.42 at the time of this writing on Wednesday morning. Since the current price is $105.42, this makes LeMaitre's 2,818 shares worth $187,101.
<h3>Delving into LeMaitre Vascular's Background</h3>
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.
<h3>Breaking Down LeMaitre Vascular's Financial Performance</h3>
Revenue Growth: Over the 3 months period, LeMaitre Vascular showcased positive performance, achieving a revenue growth rate of 15.63% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Key Profitability Indicators:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 67.82%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): LeMaitre Vascular's EPS reflects a decline, falling below the industry average with a current EPS of 0.5.
</li>
</ul>
Debt Management: LeMaitre Vascular's debt-to-equity ratio is below the industry average. With a ratio of 0.06, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Valuation Overview:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 57.93 is lower than the industry average, implying a discounted valuation for LeMaitre Vascular's stock.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 11.21 is above industry norms, reflecting an elevated valuation for LeMaitre Vascular's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Indicated by a lower-than-industry-average EV/EBITDA ratio of 36.81, the company suggests a potential undervaluation, which might be advantageous for value-focused investors.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>A Closer Look at Important Transaction Codes</h3>
Taking a closer look at transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, meticulously cataloged in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A signifies a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001158895">Check Out The Full List Of LeMaitre Vascular's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Witnessing An Insider Decision, George LeMaitre Exercises Options Valued At $187K At LeMaitre Vascular

On November 19, it was revealed in an SEC filing that Bridget Ross, Board Member at LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) executed a significant exercise of company stock options.
What Happened: Ross, Board Member at LeMaitre Vascular, exercised stock options for 3,750 shares of LMAT stock. This information was disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001158895/000143774924035773//Archives/edgar/data/1158895/000143774924035773/0001437749-24-035773-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday. The exercise price of the options was $30.0 per share.
LeMaitre Vascular shares are trading, exhibiting down of 0.0% and priced at $103.74 during Wednesday's morning. This values Ross's 3,750 shares at $276,525.
<h3>Get to Know LeMaitre Vascular Better</h3>
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.
<h3>LeMaitre Vascular: A Financial Overview</h3>
Revenue Growth: Over the 3 months period, LeMaitre Vascular showcased positive performance, achieving a revenue growth rate of 15.63% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Insights into Profitability:
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 67.82%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, LeMaitre Vascular exhibits below-average bottom-line performance with a current EPS of 0.5.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.06.
Evaluating Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 57.0 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 11.03 is above industry norms, reflecting an elevated valuation for LeMaitre Vascular's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 36.2, LeMaitre Vascular's EV/EBITDA ratio reflects a below-par valuation compared to industry averages signalling undervaluation
</li>
</ul>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Uncovering the Importance of Insider Activity</h3>
While insider transactions provide valuable information, they should be part of a broader analysis in making investment decisions.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>The Insider's Guide to Important Transaction Codes</h3>
When dissecting transactions, the focal point for <a href="https://www.benzinga.com/money/investing-tools">investors</a> is often those occurring in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001158895">Check Out The Full List Of LeMaitre Vascular's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Bridget Ross At LeMaitre Vascular Decides to Exercises Options Worth $276K

WIIM

LeMaitre Vascular shares are trading higher after Barrington Research and Oppenheimer raised their respective price targets on the stock.

Oppenheimer analyst Suraj Kalia reiterates LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) with a Outperform and raises the price target from $90 to $93.

Reiteration

Oppenheimer Reiterates Outperform on LeMaitre Vascular, Raises Price Target to $93

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Rosenblatt raised Apple Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) price target from $261 to $262. Rosenblatt analyst Barton Crockett maintained a Buy rating. Apple shares closed at $225.91 on Thursday. <a href="https://www.benzinga.com/quote/PATK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital raised the price target for Patrick Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PATK#NASDAQ">PATK</a>) from $150 to $155. BMO Capital analyst Tristan Thomas-Martin maintained an Outperform rating. Patrick Industries shares closed at $125.98 on Thursday. <a href="https://www.benzinga.com/quote/PATK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Macquarie boosted the price target for Norwegian Cruise Line Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) from $24 to $30. Macquarie analyst Paul Golding maintained an Outperform rating. Norwegian Cruise Line shares closed at $25.34 on Thursday. <a href="https://www.benzinga.com/quote/NCLH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barrington Research increased LeMaitre Vascular, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) price target from $92 to $93. Barrington Research analyst Michael Petusky maintained an Outperform rating. LeMaitre Vascular shares settled at $88.39 on Thursday. <a href="https://www.benzinga.com/quote/LMAT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Susquehanna raised Mastercard Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) price target from $540 to $605. Susquehanna analyst James Friedman maintained a Positive rating. Mastercard shares closed at $499.59 on Thursday. <a href="https://www.benzinga.com/quote/MA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Tigress Financial raised Travel + Leisure Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNL#NYSE">TNL</a>) price target from $58 to $64. Tigress Financial analyst Ivan Feinseth maintained a Buy rating. Travel + Leisure shares closed at $47.81 on Thursday. <a href="https://www.benzinga.com/quote/TNL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>RBC Capital increased the price target for Bausch Health Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHC#NYSE">BHC</a>) from $10 to $11. RBC Capital analyst Douglas Miehm maintained a Sector Perform rating. Bausch Health shares settled at $9.20 on Thursday. <a href="https://www.benzinga.com/quote/BHC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Macquarie cut Hyatt Hotels Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>) price target from $165 to $164. Macquarie analyst Chad Beynon maintained an Outperform rating. Hyatt shares closed at $145.45 on Thursday. <a href="https://www.benzinga.com/quote/MSHFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Benchmark increased the price target for The Marcus Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCS#NYSE">MCS</a>) from $20 to $22. Benchmark analyst Mike Hickey maintained a Buy rating. Marcus shares closed at $18.87 on Thursday. <a href="https://www.benzinga.com/quote/MCS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Evercore ISI Group boosted Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) price target from $240 to $260. Evercore ISI Group analyst Mark Mahaney maintained an Outperform rating. Amazon shares closed at $186.40 on Thursday. <a href="https://www.benzinga.com/quote/AMZN/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying AAPL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="547" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01120927/image-5-1024x547.png" alt="" class="wp-image-625906" style="width:659px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01120927/image-5-1024x547.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01120927/image-5-300x160.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01120927/image-5-768x411.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01120927/image-5.png 1212w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41685620/top-3-energy-stocks-that-are-preparing-to-pump-in-november">Top 3 Energy Stocks That Are Preparing To Pump In November</a></li>
</ul>

Analysts' ratings for LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $95.25, a high estimate of $100.00, and a low estimate of $92.00. This current average reflects an increase of 9.48% from the previous average price target of $87.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1730476854_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive LeMaitre Vascular. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$93.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Ross Osborn</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Neutral</td>
<td>$96.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$92.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Daniel Stauder</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$100.00</td>
<td>$77.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to LeMaitre Vascular. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of LeMaitre Vascular compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for LeMaitre Vascular's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into LeMaitre Vascular's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LMAT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on LeMaitre Vascular analyst ratings.</a>
<h2>Get to Know LeMaitre Vascular Better</h2>
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.
<h3>A Deep Dive into LeMaitre Vascular's Financials</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Over the 3 months period, LeMaitre Vascular showcased positive performance, achieving a revenue growth rate of 11.44% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: LeMaitre Vascular's net margin is impressive, surpassing industry averages. With a net margin of 21.18%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): LeMaitre Vascular's ROE stands out, surpassing industry averages. With an impressive ROE of 3.77%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): LeMaitre Vascular's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.3%, the company showcases efficient use of assets and strong financial health.
Debt Management: LeMaitre Vascular's debt-to-equity ratio is below the industry average. With a ratio of 0.06, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

In-Depth Examination Of 4 Analyst Recommendations For LeMaitre Vascular

Barrington Research analyst Michael Petusky maintains LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) with a Outperform and raises the price target from $92 to $93.

Barrington Research Maintains Outperform on LeMaitre Vascular, Raises Price Target to $93

LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) raises FY2024 GAAP EPS guidance from $1.82-1.91 to $1.91-1.96 vs $1.85 analyst estimate. Raises FY2024 sales outlook from $216.80 million-220.80 million to $219.00 million-221.00 million vs $218.32 million estimate.

Guidance

LeMaitre Vascular Raises FY2024 GAAP EPS Guidance from $1.82-1.91 to $1.91-1.96 vs $1.85 Est; Raises FY2024 Sales Guidance from $216.80M-220.80M to $219.00M-221.00M vs $218.32M Est

LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate of $0.44 by 11.36 percent. The company reported quarterly sales of $54.819 million which beat the analyst consensus estimate of $53.503 million by 2.46 percent. This is a 15.63 percent increase over sales of $47.411 million the same period last year.

LeMaitre Vascular Q3 2024 GAAP EPS $0.49 Beats $0.44 Estimate, Sales $54.819M Beat $53.503M Estimate

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>BTIG analyst Gregory Lewis initiated coverage on DHT Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHT#NYSE">DHT</a>) with a Buy rating and announced a price target of $16. DHT shares fell 3.2% to close at $11.34 on Monday. <a href="https://www.benzinga.com/quote/DHT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Berenberg analyst Nay Soe Naing initiated coverage on Synopsys, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPS#NASDAQ">SNPS</a>) with a Buy rating and announced a price target of $660. Synopsys shares gained 1% to close at $545.46 on Monday. <a href="https://www.benzinga.com/quote/SNPS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cantor Fitzgerald analyst Ross Osborn initiated coverage on LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) with a Neutral rating and announced a price target of $96. LeMaitre Vascular shares gained 1.7% to close at $92.14 on Monday. <a href="https://www.benzinga.com/quote/LMAT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Benchmark analyst Michael Albanese initiated coverage on MarineMax, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HZO#NYSE">HZO</a>) with a Buy rating and announced a price target of $40. MarineMax shares gained 5.3% to close at $33.13 on Monday. <a href="https://www.benzinga.com/quote/HZO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Ryan Levine initiated coverage on Constellation Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) with a Neutral rating and announced a price target of $284. Constellation Energy shares gained 2.1% to close at $271.74 on Monday. <a href="https://www.benzinga.com/quote/CEG/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying SNPS stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="500" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/15093223/image-116-1024x500.png" alt="" class="wp-image-596155" style="width:618px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/15093223/image-116-1024x500.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/15093223/image-116-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/15093223/image-116-768x375.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/15093223/image-116.png 1357w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More:<a href="https://www.benzinga.com/markets/24/10/41327296/jim-cramer-is-worried-about-this-plane-maker-says-palo-alto-is-a-good-one"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41327296/jim-cramer-is-worried-about-this-plane-maker-says-palo-alto-is-a-good-one">Jim Cramer Is Worried About This Plane Maker, Says Palo Alto Is A &#8216;Good&#8217; One</a></li>
</ul>

4 analysts have shared their evaluations of LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated LeMaitre Vascular and provided 12-month price targets. The average target is $95.0, accompanied by a high estimate of $100.00 and a low estimate of $92.00. Marking an increase of 14.91%, the current average surpasses the previous average price target of $82.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1728993722_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive LeMaitre Vascular. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ross Osborn</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Neutral</td>
<td>$96.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$92.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Daniel Stauder</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$100.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$92.00</td>
<td>$79.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to LeMaitre Vascular. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of LeMaitre Vascular compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of LeMaitre Vascular's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into LeMaitre Vascular's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/LMAT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on LeMaitre Vascular analyst ratings.</a>
<h2>Unveiling the Story Behind LeMaitre Vascular</h2>
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.
<h3>LeMaitre Vascular: Financial Performance Dissected</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: LeMaitre Vascular's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 11.44%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: LeMaitre Vascular's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 21.18%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.77%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): LeMaitre Vascular's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.3%, the company showcases efficient use of assets and strong financial health.
Debt Management: LeMaitre Vascular's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.06.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Scoreboard: 4 Ratings For LeMaitre Vascular

Cantor Fitzgerald analyst Ross Osborn initiates coverage on LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) with a Neutral rating and announces Price Target of $96.

Cantor Fitzgerald Initiates Coverage On LeMaitre Vascular with Neutral Rating, Announces Price Target of $96

Barrington Research analyst Michael Petusky maintains LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) with a Outperform and maintains $92 price target.

Barrington Research Maintains Outperform on LeMaitre Vascular, Maintains $92 Price Target

Acadia Healthcare Company, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/achc#NASDAQ">ACHC</a>) and Methodist Jennie Edmundson Hospital recently conducted a groundbreaking ceremony for a cutting-edge behavioral health hospital in Council Bluffs, IA. Plans to establish the hospital were announced in July 2023 as part of the joint-venture partnership between ACHC and Omaha-based Methodist Health System. The Methodist Jennie Edmundson Hospital is part of Methodist Health System.&nbsp;
The new facility will be named Methodist Jennie Edmundson Behavioral Health and is likely to commence operations in 2026. It will feature 96 inpatient beds, with 24 specifically designated for addressing the mental health needs of children and adolescents. It will also offer intensive outpatient services. The hospital will invest in cutting-edge technology and resources to enhance access to high-quality behavioral health services for patients dealing with acute mental health and substance use disorders.
This, in turn, is expected to bring about improved health outcomes for residents of western Iowa and eastern Nebraska. Working closely with local organizations, hospitals and first responders of the two regions will enable the joint venture partners to better serve the targeted regions.
<h2>A Time-Opportune Move on ACHC&#39;s Part</h2>
Opening the Methodist Jennie Edmundson Behavioral Health Hospital is likely to be a time-opportune move considering the dire need for acute and intensive outpatient behavioral health services across the Council Bluffs community. According to the American Hospital Directory, there remains a shortage of more than 300 inpatient behavioral health beds in Iowa and Nebraska, which further substantiates the timeliness of the recent move.
<h2>Benefits to Acadia Healthcare</h2>
New facilities resulting from joint ventures offer a means for ACHC to serve a greater number of patients and earn more revenues.&nbsp;
Acadia Healthcare often resorts to buyouts or joint ventures with renowned U.S. health systems to inaugurate new hospitals or expand existing facilities through bed additions. Its healthcare portfolio comprised 258 behavioral healthcare facilities across 38 states and Puerto Rico as of June 30, 2024. Management anticipates adding more than 400 beds to existing facilities in 2024.
<h2>ACHC Stock&#39;s Price Performance</h2>
Shares of Acadia Healthcare have gained 19.2% in the past month compared with the industry&#39;s 8.5% growth.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/4d/75809.jpg?v=356746199" />
Image Source: Zacks Investment Research
<h2>Zacks Rank &amp; Key Picks</h2>
ACHC currently carries a Zacks Rank #3 (Hold).&nbsp;
Some better-ranked stocks in the Medical space are LeMaitre Vascular, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lmat#NASDAQ">LMAT</a>)&nbsp;, Avanos Medical, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/avns#NYSE">AVNS</a>) and The Ensign Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ensg#NASDAQ">ENSG</a>). While LeMaitre Vascular sports a Zacks Rank #1 (Strong Buy), Avanos Medical and Ensign Group carry a Zacks Rank #2 (Buy) at present.
LeMaitre Vascular&#39;s earnings surpassed the Zacks Consensus Estimate in each of the last four quarters, the average surprise being 8.87%. The Zacks Consensus Estimate for LMAT&#39;s 2024 earnings implies an improvement of 37% while the same for revenues indicates growth of 13% from the respective 2023 figures.
The Zacks Consensus Estimate for LMAT&#39;s&nbsp; earnings has moved 4.5% north in the past 30 days. Shares of LeMaitre Vascular have gained 2.4% in the past month.
Avanos Medical&#39;s earnings surpassed estimates in three of the last four quarters and missed the mark once, the average surprise being 5.69%. The Zacks Consensus Estimate for AVNS&#39; 2024 earnings indicates a 35% rise from the 2023 figure.
The consensus mark for AVNS&#39;&nbsp; earnings has moved 0.7% north in the past 30 days. Shares of Avanos Medical have gained 6.1% in the past month.
Ensign Group&#39;s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 1.40%. The Zacks Consensus Estimate for ENSG&#39;s 2024 earnings indicates an 14.1% rise while the same for revenues implies an improvement of 13.1% from the respective 2023 reported figures.&nbsp;
The consensus mark for ENSG&#39;s earnings has moved up 0.7% in the past 30 days.&nbsp; Shares of Ensign Group have gained 1.8% in the past month.
<a href="https://www.zacks.com/stock/news/2328512/acadia-healthcare-expands-behavioral-health-services-in-iowa?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2328512">To read this article on Zacks.com click here.</a>

Press Releases

LeMaitre Will Announce Second Quarter 2024 Earnings Results August 1, 2024

LeMaitre Q2 2024 Financial Results

LeMaitre to Participate at Upcoming Investor Conferences in September

LeMaitre Will Announce Third Quarter 2024 Earnings Results October 31, 2024

LeMaitre Q3 2024 Financial Results

LeMaitre to Participate at Upcoming Investor Conferences in November

LeMaitre to Participate at Upcoming Investor Conferences in December

LeMaitre Vascular Announces Proposed Convertible Senior Notes Offering

Financing

LeMaitre Vascular Prices $150 Million Convertible Senior Notes

LeMaitre Will Announce Fourth Quarter 2024 Earnings Results February 27, 2025

Artivion

Alphatec Holdings

AtriCure

Axogen

Beta Bionics

Butterfly Network, Inc. Class A Common Stock

Butterfly Network

CeriBell

Conmed

Enovis

Paragon 28

Glaukos

Integra LifeSciences Holdings Corporation - Common Stock

Integra Lifesciences

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems

iRhythm Technologies, Inc. - Common Stock

iRhythm Technologies

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

NovoCure

Envista Holdings Corporation Common Stock

Envista Holdings

Omnicell

Pulse Biosciences

PROCEPT BioRobotics Corporation - Common Stock

PROCEPT BioRobotics

QuidelOrtho

Teleflex

TransMedics Gr

Tandem Diabetes Care, Inc. - Common Stock

Comments

LeMaitre Vascular

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga